Mr Mark Diamond is a senior pharmaceutical executive with a demonstrated record of achievement and leadership over more than thirty years within the pharmaceutical and biotechnology industries. In May 2023, Mr Diamond retired from ASX listed Antisense Therapeutics Limited as Managing Director and CEO, a position he had held since 2001, making him at the time of his retirement the longest serving CEO of a publicly traded Healthcare Company on the ASX. At Antisense, Mr Diamond was responsible for capital market engagement, pipeline development, product out-licensing and clinical trial conduct among other significant accomplishments. In 2022, Mr. Diamond was the recipient of The Biotech Daily CEO of the Year award. Prior to his time at Antisense, Mr Diamond served in senior product and business development roles at Faulding Pharmaceuticals (now Pfizer) within their US, European and international pharmaceutical operations.
Mr Diamond holds a Bachelor of Science degree from Monash University and an MBA from Macquarie University.